Centiva Capital, LP Seagen Inc. Transaction History

Centiva Capital, LP

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 14, 2023	BUY	$191.51 - $216.16 $35.5 Million - $40 Million	185,240 Added 323.19%	242,556 $51.5 Million
Q2 2023 Aug 14, 2023	BUY	$187.64 - $206.25 $5.82 Million - $6.4 Million	31,017 Added 117.94%	57,316 $11 Million
Q1 2023 May 15, 2023	BUY	$127.59 - $203.08 $3.08 Million - $4.9 Million	24,147 Added 1122.07%	26,299 $5.32 Million
Q4 2022 Feb 14, 2023	BUY	$117.37 - $139.17 $252,580 - $299,493	2,152 New	2,152 $276,000
Q3 2021 Nov 15, 2021	SELL	$142.45 - $169.82 $1.9 Million - $2.26 Million	-13,318 Closed	0 $0
Q2 2021 Aug 16, 2021	BUY	$135.08 - $161.1 $641,089 - $764,580	4,746 Added 55.37%	13,318 $2.1 Million
Q1 2021 May 17, 2021	BUY	$137.51 - $190.8 $668,573 - $927,669	4,862 Added 131.05%	8,572 $1.19 Million
Q4 2020 Feb 16, 2021	BUY	$164.63 - $211.93 $610,777 - $786,260	3,710 New	3,710 $650,000

1.26M

23K

55.2K

Ticker SGEN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 185,664,992
Description
Seagen Inc., a biotechnology company, develops and commercializes therapies for the treatment of cancer in the United States and internationally. The company offers ADCETRIS, an antibody-drug conjugate (ADC) for the treatment of patients with Hodgkin lymphoma or CD30-positive T-cell lymphomas; PADCEV, an ADC targeting Nectin-4 for the treatment ...

Get notified when there are updates to the investment portfolio of Centiva Capital, LP, based on Form 13F filings with the SEC.

Stay updated on Centiva Capital, LP with notifications on news.